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Summary 
Presentation of antigen by the major histocompatibility complex to T lymphocytes without the 
requisite costimulatory signals does not induce an immune response but rather results in a state 
of antigen-specific unresponsiveness, termed anergy. To determine which costimulatory signals 
are critical for the T cell commitment to activation or anergy, we developed an in vitro model 
system that isolated the contributions of alloantigen and each candidate costimulatory molecule. 
Here, we show that transfectants expressing HLA-DR7 and either B7 or intercellular adhesion 
molecule 1 (ICAM-1) deliver independent costimulatory signals resulting in aUoantigen-induced 
proliferation of CD4-positive T lymphocytes. Although equivalent in their ability to costimulate 
maximal proliferation of alloreactive T cells, B7 but not ICAM-1 induced detectable interleukin 
2 secretion and prevented the induction of alloantigen-specific anergy. These results are consistent 
with the hypothesis  that blockade of the ICAM-l:lymphocyte function-associated  1 pathway 
results in immunosuppression, whereas blockade of the B7:CD28/CTLA4 pathway results in 
alloantigen-specific  anergy. This approach, using this model system, should facilitate  the identification 
of critical costimulatory pathways which must be inhibited in order to induce alloantigen-specific 
tolerance before human organ transplantation. 
T 
he success of human allogeneic organ transplantation, 
which is presently dependent upon toxic nonspecific im- 
munosuppression, would be improved substantially if it were 
possible to induce long-lasting specific tolerance to alloan- 
tigen. One approach to achieve this objective is to present 
alloantigen to  T  lymphocytes in the absence of requisite 
costimulatory signal(s). This therapeutic concept is based on 
considerable evidence that demonstrates that T lymphocytes 
must receive two signals from APCs to induce an antigen- 
specific response (1-5).  The first signal, which confers an- 
tigen specificity, requires the TCR complex to recognize for- 
eign antigenic peptide presented in association with the MHC 
complex on the surface of APCs. This interaction between 
the TCR complex and antigen MHC is necessary but not 
sufficient for T cell activation (6). The outcome of TCR en- 
gagement is determined by additional signals, termed costimu- 
latory, provided by one or more cell surface molecules ex- 
pressed on APCs (7). These costimulatory signals are neither 
antigen specific, nor MHC restricted, yet they are critical for 
the induction of maximal T cell proliferation, cytokine secre- 
tion,  and  effector  function.  Therefore,  when  antigen  is 
presented by MHC without appropriate costimulation, func- 
tional unresponsiveness of antigen-specific T lymphocytes is 
induced (1, 2, 4,  8). 
A number of ligands expressed on APCs and their receptors 
expressed on T cells are candidates for critical costimulatory 
signals including: B7:CD28/CTLA4  (9-14); intercellular adhe- 
sion molecule I (ICAM-1) I (CD54), -2, -3:LFA-1 (CDlla/ 
CD18) (15-20); LFA-3 (CD58): CD2 (21-23); CD40:CD40 
ligand (24, 25); and heat stable antigen (CD24): heat stable 
antigen (CD24) (26). Although each of these ligand: receptor 
pairs have been reported to have costimulatory potential, their 
relative importance in regulating alloantigen-mediated T cell 
proliferation,  lymphokine production, and/or in preventing 
the induction of tolerance remains unresolved. Previous studies 
(17, 19, 27) have demonstrated that the ICAM-I:LFA-1 ligand- 
receptor pair can costimulate T cell proliferation and that in- 
hibition Of this pathway can prolong murine allograft  sur- 
vival  (28). In  contrast,  recent  studies  demonstrate  the 
1 Abbreviations used in this paper: allo-APC, alloantigen-presenting cell; 
CsA, Cylosporin  A; ICAM-1,  intercellular adhesion  molecule 1; IM, calcium 
ionophore Ionomycin;  LBL, lymphobhstoid  B cell line; mito-C, mitomycin- 
C; MLR, mixed lymphocyte reaction. 
1753  J. Exp. Med. ￿9  The Rockefeller University Press ￿9  0022-1007/93/11/1753/I1  $2.00 
Volume 178  November  1993  1753-1763 B7:CD28/CTLA4 ligand-receptor pair not only induces T 
cell proliferation and IL-2 production (10, 11), but also pre- 
vents the induction of antigen-specific tolerance (29, 30). Two 
recent murine in vivo experiments corroborate the apparent 
signifcance of this costimulatory pathway since blockade of 
the B7:CD28/CTLA4 pathway results in long-lasting toler- 
ance to human xenoantigen and prolongation of  murine cardiac 
allograft survival  (31, 32). 
In light of the large number of candidate costimulatory 
molecules and their potential to prevent the induction of toler- 
ance, we have developed an in vitro system that evaluates the 
capacity of ligands to costimulate alloantigen-induced T cell 
recognition and, more importantly, to determine whether 
these costimulatory molecules can prevent the induction of 
alloantigen-specific  tolerance.  In the studies reported below, 
we demonstrate that although both B7  and ICAM-1  are 
equally potent costimulators of T cell proliferation, only B7 
costimulation prevents  the induction of alloantigen-specific 
anergy. These results are  consistent with the notion that 
blockade of the ICAM-I:LFA-1 pathway results in inhibi- 
tion of primary response  to alloantigen, whereas blocking 
the B7:CD28/CTLA4 costimulatory pathway results both 
in inhibition of primary response  and in specific tolerance 
to alloantigen. 
Materials and Methods 
Human  T  Cells.  PBMC were isolated from HLA-DK7 and 
DRl-negative  healthy donors by density gradient centrifugation 
on Ficoll-Hypaque. Monocytes were depleted by adherence on 
plastic. The CD4 + T cell population was further enriched by sepa- 
ration from residual monocytes, B ceils, NK cells, and CD8 + T 
cells by mAb and complement lysis, using anti-CD14 (Mo2), anti- 
CDllb (Mol), anti-CD20 (B1), anti-CD16 (3G8), and anti-CD8 
(7FF 3F9) mAbs. The efficiency  of the purification was analyzed 
in each case by flow cytometry (Epics Elite; Coulter Electronics, 
Hialeah, FL), using anti-CD3, anti-CD4, anti-CD8, and anti-CD14 
mAbs followed by FITC-conjugated goat anti-mouse Ig (Fisher 
.Scientific  Co., Pittsburgh, PA). The final  cell preparation  was always 
;>99% CD3 +, >99% CD4 +, <1% CD8 §  , and <1% CD14  +  . Be- 
fore use, calls were resuspended in complete culture medium con- 
sisting of RPMI 1640 with 10% heat-inactivated  FCS, 2 mM gluta- 
mine, 1 mM sodium pyruvate, penicillin (100 U/ml), streptomycin 
sulfate (100 #g/m1), and gentamicin sulfate (5 gg/ml). 
Monoclonal Antibodies and Fusion Proteins,  mAbs  were used as 
purified Ig unless indicated otherwise: anti-B7 (mAb 133): IgM 
(33); anti-CD20: B1, IgG2a (34); anti-B5: IgM (35); anti-CD19: 
134, IgG1 (36); anti-CD8: 7PT 3F9, IgG2a; anti-CDllb: Mol, IgM 
and anti-CD14: Mo2, IgM (37); anti-MHC class II: 9-49, IgG2a 
(Dr. K. Todd, University of Michigan, Ann Arbor, MI) (38); anti- 
CD28: 9.3, IgG2a (Dr. C. June, Naval Research Institute, Bethesda, 
ME)) (39); anti-ICAM-l:  RRI.1,  IgG1 (40) and  anti-LFA-la: 
TS1/22, IgG1 (41) (Dr. T. Springer, Center for Blood Research, 
Boston, MA); and anti-CD16: 3G8, IgG1 (used as ascites) (Dr. 
J. Ritz, Dana Farber Cancer Institute). Anti-CD28 Fab fragments 
were generated in our laboratory from the 9.3 mAb, by papain 
digestion and purification on a protein A column, according to 
the manufacturer's instructions  (Pierce, Rockford, IL). Human 
CTLA4-Ig was prepared as previously described (30). Control fu- 
sion protein (control Ig), was identically constructed, except  using 
a recombinant human-mouse chimeric mAb in which the H and 
L chain variable domains were derived from a murine anti-HIV 
envelope mAb, and the remainder of the chimeric mAb was de- 
rived from the identical human IgG1 sequences used to construct 
CTLA4-Ig. The chimeric  control mAb was purified  on an immobi- 
lized protein A column and did not react with either human or 
murine lymphocytes as measured by flow cytometry. 
NIH 3T3 Cell Transfection.  The MHC class II-negative, B7- 
negative routine fibroblast cell line NIH 3T3, was transfected by 
electroporation with either/)Rot and DR7~ chain (t-DR7), B7 
(t-B7), ICAM-1  (t-ICAM-1), DRcr,  DR7~  chain  and B7  (t- 
DR7/B7) or DRcr, DR7~ chain and ICAM-1  (t-DR7/ICAM-1) 
genes. The preparation of t-DR7, t-B7, and t-DR7/B7 transfec- 
tants has been previously described (30). t-mock cells were con- 
structed  by transfecting the SV2-Neo-Sp65 plasmid only.  For 
ICAM-1 transfection, a plasmid encoding human ICAM-1 in the 
pH3M  vector ([27], kindly provided by Dr.  Brian Seed, Mas- 
sachusetts General Hospital, Boston, MA) was used. For each trans- 
fection, 20 #g of Sill linearized ICAM-1 plasmid and 5 #g of ClaI 
linearized pPGK-Hygro were electroporated into NIH 3T3 cells 
or into t-DR7 cells. After selection  in media containing 400 gg/ml 
Hygromycin B (Calbiochem-Novabiochem  Corp., La Jolla, CA) 
for t-ICAM-1 or 200 #g/ml G418 (GIBCO BRL, Gaithersburg, 
MD) and 400 gg/ml Hygromycin  B for t-DK7/ICAM-1, cells  were 
sorted for ICAM-1 and DR expression  by indirect immunofluores- 
cence, cultured for 4 wk, resorted, and cloned by limiting dilu- 
tion. Transfectants  expressing similar  levels of  DR and/or ICAM-1 
were selected  for use. The expression  of ICAM-1 was assessed  using 
the RRI.1 mAb. The expression of MHC class II and B7 were 
assessed using the mAbs 9-49 and 133, respectively. These cells 
are referred to as artificial  alloantigen-presenting cells (allo-APCs) 
throughout the text. Before use, allo-APCs were treated with 10 
gg/ml mitomycin-C (mito-C) (Sigma Chemical Co., St. Louis, 
MO), at 37~  for 4 h, washed  extensively,  and resuspended  in com- 
plete culture medium. The required number of cells was added to 
the appropriate wells in 96-well flat bottomed microtiter plates 
(Nunc, Koskilde, Denmark) and incubated overnight at 37~  in 
5%, before the addition of the responder T cells. 
Primary Mixed Lymphocyte Reaction (MLR).  To determine the 
appropriate numbers of NIH 3T3  transfected cells bearing the 
allogeneic dass II molecule (t-DR7) required to induce a submito- 
genie signal for T cell activation, a dose-response curve was per- 
formed using 10  s CD4 + T cells/well as responders, and progres- 
sively, increasing numbers  of mito-C-treated  t-DR7  cells as 
stimulators. The  dose of 5  x  104  cells/well was  the highest 
number of t-DR7 that did not induce allogeneic T cell prolifera- 
tion. All primary MLRs were performed using 5  x  104 stimu- 
lators/well. For experiments with Cyclosporin A (CsA) (Sandoz 
Pharmaceuticals, East Hanover, NJ) used at a final  concentration 
of 10 -6 M, T cells were incubated with CsA for 10 min at 4~ 
before the initiation of culture. When indicated, stimulator NIH 
3T3 cells were incubated for 30 min at 4~  with either 10 #g/ml 
anti-MHC dass II, anti-B7, or anti-ICAM-1 mAbs, or 10 #g/ml 
CTLA4-Ig or control-Ig before addition to the experimental  plates. 
Similarly, responder CD4 + T cells were incubated with 15 gg/ml 
anti-CD28 Fab or 10 #g/ml anti-LFA-1, for 30 min at 4~  To 
assess the kinetics of primary response, eight identical plates for 
each condition were set up and harvested daily from day 1 to 8 
after the initiation of  culture. For experiments with mixed popula- 
tions of t-DR7 and t-ICAM-1 or t-B7 cells as stimulators, equal 
numbers of the two different types of transfectants were mixed 
and the indicated numbers of cells were used as stimulators. 
Secondary Stimulation.  After the appropriate time for maximal 
response in a primary MLR (7 d of  culture with t-DK7 or t-DR7/ 
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loreactive T  cell blasts were isolated by Percoll gradient in the 
40-50%  fraction, washed extensively, and cultured in media for 
24 h. Each T ceil population was subsequently rechallenged with 
(a) each one of the primary stimulators; (b) an irrelevant stimulator 
cell population not expressing HLA-DR7 antigen (PBMC from 
a DR1 homozygous individual) (DRI-PBMC);  (c) an EBV-trans- 
formed B7 +, lymphobhstoid B cell line from a DR7 homozygous 
individual (DR7-LBL);  (d) 100 U/ml recombinant  human IL-2  (Col- 
laborative Biomedical  Products, Bedford, MA); or (e) a mitogenic 
combination of I ng/ml PMA and 100 ng/ml calcium ionophore 
Ionomycin (IM) (both from Sigma Chemical Co.). Samples were 
cultured in triplicate at 37~  for the appropriate time period (1- 
8 d with allo-APCs DRI-PBMC or DR7-LBL and for 3 d with 
Ib2 or PMA and IM) in 5% CO2. To determine the length of 
primary exposure to alloantigen that is necessary  for the develop- 
ment of specific tolerance, T cells were cultured from 12 h-7 d 
with artificial  allo-APCs  in a primary MLR, and the above  described 
isolation of blasts and restimulation procedure was performed. 
Thyraidine Incorporation.  Thymidine incorporation was used as 
an index of mitogenic activity During the last 18 h of the appro- 
priate culture period, cells were incubated with 1 gCi (37 kBq) 
of [raethfl-3H]thymidine (Du Pont, Boston, MA). The cells were 
harvested onto filters and the radioactivity on the dried filters was 
measured in a beta plate liquid scintillation counter (Pharmacia, 
Piscataway, NJ). 
Cell Cycle Analysis.  CD4 + T cells were stimuhted in a pri- 
mary MLR, as described above, with t-DRT, t-DRT/B7,  t-DR7/ 
ICAM-1 allo-APCs, or t-DR7 and IL-2. After the completion of 
the appropriate time for maximal response, viable alloreactive T 
cells were  recovered as  described  above and  106  ceils were 
resuspended in 500/A of propidium iodide solution (propidium 
iodide 50 gg/ml [Sigma Chemical Co.], 0.1% NP-40, and 0.1% 
Na citrate). After incubation for 30 min at 4~  DNA analysis 
was performed by flow cytometer (Coulter Electronics). As con- 
trois, T cells were cultured in media for 5 and 7 d and DNA prepa- 
ration was performed. 
11_,2 and IG4 Assays.  Supernatants from primary and secondary 
stimulations were collected at 24 and 48 h after the initiation of 
the culture, as indicated, and Ib2 and ID4 concentrations were 
assayed  in duplicate  by ELISA  (R & D Systems,  Minneapolis, MN). 
Results 
B7 and ICAM-I  Provide Distinct  Costiraulatory Signals for 
Proliferation of Alloreactive CD4 + T  Cells.  Considering the 
number of candidate costimulatory molecules that might be 
expressed  on the cell surface of normal human allo-APCs, 
transfectants expressing HLA-DR7, B7, and ICAM-1 either 
alone or in combination, were prepared in order to function- 
ally  dissect  the  B7:CD28/CTLA4  and  ICAM-I:LFA-1 
costimulatory pathways. These artificial allo-APCs were con- 
structed by stably transfecting (a) HLA-DRot  and -DR7~ 
chain genes (t-DRT); (b) B7 gene (t-B7); (c) ICAM-1  gene 
(t-ICAM-1); (d) the combination of HLA-DRat and -DR7B 
chains and B7 genes (t-DRT/BT); or (e) the combination of 
HLA-DRcr and -DR7~ chains and ICAM-1  genes (t-DRT/ 
ICAM-1) into NIH 3T3 cells, as described in Materials and 
Methods. The expression or coexpression of these genes was 
documented by FACS  |  analysis as depicted in Fig.  1. 
To determine the relative contributions of B7 and ICAM-1 
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Figure  1.  Surface  expression  of human  MHC class II, B7, and ICAM-1 
of transfected  NIH 3T3 cells. Cells  were stained  with 9-49, 133, or RRI.1 
mAb followed  by FITC-labeled  goat anti-mouse  Ig and analyzed  by flow 
cytometry. 
tO  alloantigen-induced proliferation,  CD4 +  T  cells  from 
HLA-DR7- and DRl-negative individuals were cocultured 
with mito-C-treated allo-APCs in a primary MLR for 1-8 d 
as described in Materials and Methods and proliferation was 
assessed. When increasing numbers of stimulator t-DR7 cells 
were added to constant numbers of  responder T cells, prolifer- 
ation was first observed  at a stimulator/responder ratio of 
>1:2 (Fig. 2 a). Peak t-DR7 induced proliferation occurred 
at 7 d of culture at a stimulator/responder ratio of 1:1 and 
declined thereafter. Increasing numbers of t-B7 or t-ICAM-1, 
up  to  stimulator/responder  ratio  of  1:1  did  not  induce 
significant proliferation of T cells (Fig. 2, b and c) compared 
to controls cultured with autologous T cells or mito- C-treated 
t-mock transfectants (data not shown). At concentrations at 
which t-DR7 cells did not induce prolif~ation (stimulator/re- 
sponder ratio 1:5), t-DR7/B7 cells induced significant prolifer- 
ation, demonstrating that B7 provided a costimulatory signal 
to  submitogenically alloactivated T  cells  (Fig.  2  b).  Peak 
proliferation by t-DR7/B7 cells occurred at a stimulator/re- 
sponder ratio of 1:2 and was nearly threefold of that observed 
with t-DR7 cells alone. Equal numbers of t-DR7/ICAM-1 
cells provided a similar magnitude of costimulation as t-DR7/ 
B7 cells (Fig. 2 c). Although the maximal costimulatory signals 
delivered by t-DR7/B7 or t-DR7/ICAM-1 were nearly iden- 
tical, the kinetics of the response differed as B7 costimula- 
tion peaked  at 7 d whereas ICAM-1 costimulation peaked 
at 5 d  of culture (data not shown). 
Although  t-DR7/B7  and  t-DR7/ICAM-1  appear  to 
equally enhance aUoreactive T cell proliferation, this can be 
due to either transmission of a costimulatory signal or simply 
to enhanced adhesion. To address this issue, T cells were cul- 
tured with: (a) increasing numbers of equal mixed popula- 
tions of t-DR7 and t-B7; (b) increasing numbers of equal 
1755  Boussiotis  et al. ,...., 
.a 
t-DR7 
2  4  6  8  10 
b  t.DR7 / B7  - C  /  t-OR7 / ICAM-1 
' 
2  4  6  8  10  0  2  4  6  8  10 
Number of Stimulators / Wetl  ( x  10 4) 
d 
t-DR7 
+ 
t-DR7 + t-B7  t-ICAM-1 
\ 
2  4  6  8  10 
Figure  2.  Dose-response of CD4 + T cells to alloantigen, presented on allo-APCs with or without B7 or ICAM-1 costmulation. 10  s T cells were 
cultured with increasing numbers of each type of NIH 3T3 transfectants as stimulators, and thymidine incorporation was assessed for the last 18 h 
of a 7-d culture with t-DR7, t-B7, or t-DR7/B7 and of a 5-d culture with t-ICAM-1 or t-DK7/ICAM-1. In experiments in which mixed populations 
of transfectants were used as stimulators (d), cell numbers were selected so that DK7 molecules and costimulatory molecules per well were equal to 
those present on the corresponding double transfectants t-DR7/B7 and t-DR7/ICAM-1; the indicated numbers represent those of each cell type. This 
represents one of  three experiments with mixed populations of  t-DK7 and t-mock as stimulators, and five  additional experiments under all other indicated 
conditions. 
mixed populations of t-DR7 and t-ICAM-1; and (c) submito- 
genic concentrations of PMA and t-ICAM-1 or t-B7 cells. 
As seen in Fig. 2 d, t-DR7 and t-B7 or t-DR7 and t-ICAM-1 
allo-APCs provided costimulatory signals of comparable mag- 
nitude, beginning at stimulator/responder ratios of 1:5. Al- 
though the maximal response induced by these mixed popu- 
lations was not markedly augmented compared to that induced 
by t-DR7 alone, it occurred at a low stimulator/responder 
ratio, at which t-DR7 did not induce T  cell response. How- 
ever, in all experiments, proliferative response induced by mixed 
populations of transfectants was significantly less than that 
induced by either t-DK7/B7 or t-DK7/ICAM-1. No signifi- 
cant additive stimulatory effect was observed by mixed popu- 
lations  of  t-DR7  and  t-mock.  Mito-C-treated  t-B7  or 
t-ICAM-1 allo-APCs in the presence of submitogenic con- 
centrations  of PMA, equally costimulated T  cell prolifera- 
tion (Table 1). No costimulation was induced by t-mock cells 
(data not shown).  Although both ICAM-1 and B7 are in- 
volved in adhesion between APCs and T  cells,  these results 
are  consistent  with  the  hypothesis  that  they  also  deliver 
costimulatory signals independent of their adhesive function. 
In addition, indication that B7 and ICAM-1 costimulate 
Table  1.  Effect of CsA  on B7 and ICAM.1  Costimulation of CD4 + T  Cell Proliferation and IL-2 Accumulation 
Thymidine incorporation  IL-2 
Culture  Conditions  Media  CsA  Media  CsA 
CD4§  cells 
cpm  pg/ml 
452  359  20  20 
+ PMA  4,787  4,148  <20  <20 
+ PMA + t-B7  84,888  76,150  580  320 
+ PMA + t-ICAM-1  73,130  7,555  <20  <20 
+ PMA + IM  63,134  12,871  1,100  50 
+ PMA + IM + t-B7  127,927  122,583  2,000  1,800 
+ PMA + IM + t-ICAM-1  160,030  37,293  1,200  60 
+ t-DK7/B7  37,354  33,761  1,100  800 
+ t-DR7 + t-B7  22,321  20,786  250  230 
+ t-DK7/ICAM-1  20,548  3,587  <20  <20 
+ t-DR7 + t-ICAM-1  16,654  2,966  <20  <20 
CD4 § T cells were cultured in the presence of the indicated stimuli. When activation was provided by PMA or PMA  +  IM and costimulation 
by either B7 or ICAM-1, IL-2 accumulation was assessed at 24 h and proliferation at 3 d of culture. When activation was provided by alloantigen, 
IL-2 accumulation and proliferation were assessed as described in the legend to Fig. 3. Values represent means of triplicate cultures (SEM <15%). 
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sensitivity to CsA. CD4 + T cells were activated with either 
PMA, PMA and IM, or t-DR7 allo-APCs, and costimula- 
tion was provided by either B7 or ICAM-1. As seen in Table 
1, costimulation by B7 is CsA resistant, whereas costimula- 
tion by ICAM-1 is CsA sensitive. 
B7 but Not ICAM-1  Induces Detectable IL-2 Production by 
Alloreactive  TLymFhocytes.  Since  both B7 and ICAM-1 ap- 
pear to provide equally potent costimulation for alloreactive 
T cell proliferation,  we next sought to determine whether 
they also induced IL-2 secretion. For these experiments,  to 
minimize any possible contribution from additional ligands 
that might be present  on the NIH-3T3 cells, the numbers 
of stimulators were selected so that t-DR7 cells alone, would 
not induce proliferation (stimulator/responder ratio 1:2) and 
therefore provide a submitogenic first signal. To confirm the 
specificity of the activation and costimulatory signal provided 
by the artificial allo-APCs, mAbs and fusion proteins directed 
against TCR:MHC class II, B7:CD28/CTLA4,  and ICAM-I: 
LFA-1 pathways were added at the inception of these cultures. 
At 2 d, IL-2 and IL-4 concentration in the culture superna- 
rants was assessed by ELISA and proliferation  was assessed 
at  5  d  for  t-DR7/ICAM-1  and  at  7  d  for  t-DR7/B7- 
induced response. Here, t-mock, t-DR7, and t-ICAM-1 cells 
did not induce proliferation or detectable IL-2 or IL-4 produc- 
tion (Fig. 3, a and b). Fig. 3 a examines the costimulatory 
effect of the ICAM-I:LFA-1 pathway, t-DR7/ICAM-1 cells 
delivered a significant proliferative signal that was inhibited 
by >95%  with either anti-class II, anti-ICAM-1, or anti- 
LFA-1 but not with isotype-matched  control mAbs; no IL-2 
or IL-4 accumulation was detected, t-DR7/B7 cells induced 
a proliferative response that was comparable to that induced 
by t-DR7/ICAM-1 but unlike t-DR7/ICAM-1 it was ac- 
companied by the presence of significant amounts of IL-2. 
No IL-4 accumulation was detected (Fig. 3 b). Response was 
inhibited by anti-MHC class II mAb, and the specificity of 
B7 to induce IL-2 is demonstrated by the complete abroga- 
tion of proliferation and IL-2 accumulation by blocking the 
B7:CD28/CTLA4 costimulatory pathway with either anti- 
B7  or anti-CD28  Fab  mAb,  or CTLA4-Ig (high affinity 
receptor for B7). No inhibitory effect  was observed for isotype- 
identical control mAb or control-Ig. Specificity for B7 and 
ICAM-l-mediated costimulation was confirmed since anti- 
B7,  anti-CD28  Fab  mAbs,  or CTLA4-Ig  did not  affect 
costimulation induced by t-DR7/ICAM-1, and anti-ICAM-1 
or anti-LFA-1 mAbs did not affect the costimulation induced 
by t-DRT/B7 (data not shown). 
At the completion of primary MLR with t-DR7 cells as 
stimulators,  the fraction of T cells in each phase of the cell 
cycle was not significantly different compared to the controls 
cultured with media alone (Table 2). Cocuhure with t-DR7 
and  IL-2  or  t-DR7/ICAM-1  and  more strikingly with 
t-DR7/B7,  induced T cells to enter the cell cycle and pro- 
gress to S phase. 
B7 but not ICAM-I  Costimulation  Prevents the Induction of 
Alloantigen-specific  Tolerance.  We next sought to determine 
whether alloantigen presentation in the absence of costimu- 
lation could induce alloantigen-specific tolerance and, more 
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Figure  3.  B7 and [CAM-1 mediate distinct and specific  costimulatory 
signals in primary MLR. Freshly isolated CD4 + T cells were cocuhured 
with a]lo-APCs in media or in the presence of the indicated mAbs. Anti- 
CD20 is art isotype control for anti-class II and anti-CD19 is the control 
for anti-ICAM-1 and anti-LFA-1 mAbs; anti-B5 is the control for anti-B7 
mAb and control-Ig is the control for CTLA4-Ig. Proliferation was as- 
sessed at 7 d of cuhure with t-mock, t-DR7, t-B7, t-DR7/B7 and at 5 d 
of culture with t-mock, t-DR7, t-ICAM-1, and t-DRT/ICAM-1. (a) Nine 
experiments; (b) seven experiments. IL-2 and Ib4 concentrations  shown 
were assessed in supernatants of 48 h of culture by ELISA. The concentra- 
tion of 20 pg/ml was the lowest detection limit of the assay. 
importantly, whether either B7 or ICAM-1 could prevent 
the induction of tolerance. To this end, we undertook a three- 
step culture: (a) primary sensitization oft ceils to allo-APCs; 
(b) recuhure of these cells in media; and finally (c) rechallenge 
in a secondary culture with either allo-APCs, third-party al- 
loantigen, exogenous IL-2, or mitogens. Specifically,  T cells 
were cultured with either t-DR7,  t-DR7/B7,  or t-DR7/ 
ICAM-1. Primary MLR culture was continued until the com- 
pletion of  maximal response (7 d with t-DR7 and t-DR7/B7, 
and 5 d with t-DR7/ICAM-1 allo-APCs).  After primary 
stimulation, viable alloreactive blasts from each culture were 
isolated, washed, and recuhured in media for 24 h to reex- 
press TCR complex (data not shown). These cells were then 
restimulated with (a) t-DR7, t-DR7/B7, or t-DR7/ICAM-1; Table  2.  Effect of Alloantigen and B7 or ICAM-1 
Costiraulation on Cell Cycle Progression of Alloreactive CD4 + 
T  Cells 
Percent  cells in each cell 
cycle phase 
Culture  conditions 
of CD4 §  T  cells  G0/G1  S  G2 
Media  94.3  4.4  1.9 
t-DR7  94.6  5.4  2.0 
t-DR7  +  IL-2  75.2  24.8  2.0 
t-DR7/B7  52.6  39.5  1.9 
t-DR7/ICAM-1  78.0  28.4  1.8 
CD4 +  T  cells were cultured in  a  primary  MLR with  the indicated 
stimuli  and resuspended in propidium iodide solution.  I(P T cells were 
analyzed for each sample. 
(b) a stimulator cell population not expressing DR7 antigen 
(PBMC from a DR1 homozygous individual) (DRI-PBMC); 
(c) recombinant human IL-2;  or (d) a mitogenic combina- 
tion of PMA and IM.  Proliferation was assessed at 3  d  of 
culture with IL-2 or PMA and IM and at 1-8 d of culture 
with each one of the other stimuli. As controls, T cells were 
exposed in the primary culture to either t-mock,  t-B7,  or 
t-ICAM-1. T cells recovered from these control primary cul- 
tures, demonstrated a proliferative response on rechallenge 
with either t-DR7, t-DR7/B7,  or t-DR7/ICAM-1  identical 
to that induced by these transfectants in a primary stimula- 
tion  (data  not  shown). 
When T  cells were primarily stimulated with t-DR7 or 
t-DR7/ICAM-1  allo-APCs,  they  were  tolerized  and  no 
significant proliferation was observed at restimulation with 
either  t-DR7,  t-DR7/B7,  or  t-DR7/ICAM-1  cells  (Fig. 
4 a). This proliferative response was identical to that observed 
in the controls of the secondary stimulation, in which T cells 
from each primary culture were rechallenged with either au- 
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Figure  4.  B7 but not ICAM-1 costimulation can prevent 
the  induction  of tolerance.  CD4 +  T  cell  were primarily 
stimulated  with  t-DR7,  t-DK7/B7,  or  t-DK7/ICAM-1. 
Viable blasts were rested in media for 24 h and cultured with 
a secondary stimulus, as shown. Thymidine incorporation was 
measured for the last 18 h ofa 3-d culture with either t-DR7, 
t-DK7/B7, t-DR7/ICAM-1, lb2, or PMA  +  IM and of a 
7-d culture with third-party  alloantigen as secondary stimuli. 
Results represent 18 experiments with t-DR7 or t-DR7/B7 
and seven experiments  with t-DR7/ICAM-1 stimulators  in 
primary culture.  11.,2 and Ib4 concentrations  were assessed 
in supernatants  of 48 h of secondary culture with third-party 
alloantigen  and of 24 h of secondary culture with each one 
of the other stimuli. 
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Although the tolerized cells did not respond to any of the 
above allo-APCs during the secondary challenge, there was 
significant proliferation in response to either IL-2, mitogenic 
combination of PMA and IM, or third-party alloantigen. 
In contrast, when T cells were primarily stimulated with 
t-DR7/B7 allo-APCs,  they responded to all types of allo- 
APCs in a secondary culture and the proliferative response 
peaked at day 3 (Fig. 4 b, top), characteristic of a secondary 
response. Interestingly, proliferation consistently was highest 
with t-DK7/B7 allo-APCs,  followed by t-DK7/ICAM-1, 
and to a lesser extent with t-DK7. The response to t-DK7 
occurred at a cell concentration that did not induce prolifera- 
tion in the primary MLK, suggesting that this represented 
a secondary proliferative response. Significant proliferation 
was also induced by IL-2, PMA, and IM or third-party al- 
loantigen. When the primary stimulation with t-DK7/B7 
allo-APCs was performed in the presence of CTLA4-Ig to 
block the B7:CD28/CTLA4 pathway, secondary responses 
demonstrated virtually identical results to those seen with 
T cells primarily stimulated with t-DR7 allo-APCs, i.e., the 
T cells were tolerized (Fig. 4 b, middle).  No effect was ob- 
served when control-Ig was added in the primary culture (Fig. 
4, bottom). This observation confirms that the B7 costimula- 
tory signal is sufficient  for prevention of the induction of  toler- 
ance to alloantigen. 
To determine whether seconda~  proliferative  responses  were 
driven by IL-2 or potentially by IL-4, supernatants were har- 
vested at 48 h of rechallenge with third-party alloantigen and 
at 24 h of rechallenge with each one of the other stimuli, 
and IL-2 and IL-4 concentration was assessed  by ELISA. Only 
t-DR7/B7 allo-APCs induced both detectable amounts of 
IL-2 and increased proliferation. Both alloactivated and toler- 
ized T cells, however, produced significant amounts of IL-2 
in response to mitogenic combination of PMA and IM or 
third-party alloantigen (Fig. 4). In contrast, IL-4 was detect- 
able only after secondary stimulation with PMA and IM. 
It is of note that primary sensitization in the presence of B7 
costimulation, primed the cells for IL-4 secretion in restimu- 
lation with PMA and IM (Fig. 4  b,  top). 
Since T  cells primarily sensitized with either t-DK7 or 
t-DK7/ICAM-1  did  not  proliferate  or  secrete  IL-2  on 
rechallenge  with t-DK7/B7 allo-APCs, they were rechallenged 
with a lymphoblastoid cell line (DK7-LBL) or with PBMC 
(DK1-PBMC), that express aUoanfigens  and presumably other 
costimulatory molecules not expressed on the surface of the 
transfectants.  T  cells tolerized  to  DR7  using  t-DR7  or 
t-DK7/ICAM-1 during primary stimulation, demonstrated 
low levels of proliferation after rechallenge with DK7-LBL, 
which peaked at day 7 of culture (Fig. 5, top and bottom). 
In contrast,  T  cells primarily sensitized with t-DR7/B7, 
demonstrated a dramatic secondary response on rechallenge 
with DR7-LBL, which peaked at day 3 of culture (Fig. 5, 
middle). All populations of T cells, however, responded iden- 
tically to rechallenge with third-party HLA-DR alloantigen 
expressed on the DRI-PBMC,  and proliferative  response 
peaked at day 7 of culture (Figs. 4 and 5). 
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Figure  5.  B7 costimulation in primary MLR primes CD4 § T cells for 
secondary  alloantigen-specific  response,  but does  not affect  response  to third- 
party alloantigen. CD4 + T  cells were primarily stimulated with either 
t-DR7,  t-DK7/B7, or t-DK7/ICAM-1.  Viable blasts were cultured in 
media for 24 h and restimulated with an EBV-transformed cell line from 
a DR7 homozygous individual (DR7-LBL) or with PBMC from a DR1 
homozygous individual (DRI-PBMC). At the indicated time points of 
culture, thymidine incorporation was assessed; one of seven experiments. 
To determine the time interval of primary exposure to al- 
loantigen required to induce alloantigen-specific tolerance, 
T cells were cultured with t-DR7, t-DK7/B7, or t-DR7/ 
ICAM-1 aUo-APCs for time intervals varying from 12 h to 
7 d. After primary sensitization, viable aUoreactive  blasts were 
isolated and restimulated as described above. T cells exposed 
to alloantigen, presented by either t-DR7 or t-DK7/ICAM-1 
stimulators, for periods of 24 h to 7 d, were rendered tolerant 
to the specific aUoantigen. In contrast, T cells primarily sen- 
sitized for only 12 h were not tolerized and showed a pri- 
mary response pattern at restimulation (data not shown). 
IL-2 Prevents the Induction but Cannot Reverse the State  of 
Alloantigen-specific Tolerance.  Since  B7 costimulation results 
in the production of multiple lymphokines including IL-2 
(42--44), we were interested in determining  whether the pres- 
ence of IL-2 in the primary culture was the critical factor 
for preventing the induction of tolerance or whether, alter- 
natively, B7 delivered a specific  activating signal. T cells were 
cultured with primary tolerogenic signal (t-DR7) in the pres- 
ence of media or 100 U/ml of IL-2. After primary culture, 
IL-2  was  removed,  cells were rested  for 24  h,  and  then 
rechallenged with allo-APCs for 1-8 d or PMA and IM for 
3  d.  T  ceils tolerized  with  t-DK7,  did not respond on 
rechallenge with t-DR7, t-DR7/B7, or t-DR7/ICAM-1  al- 
though they did proliferate in response to PMA and IM (Fig. 
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Figure  6.  Primary stimulation with alloantigen in the presence of Ib2 
can prevent the induction of tolerance.  CD4 +  T  cells  were primarily 
stimulated with t-DR7 with or without exogenous I1,2.  Visible blasts 
were rested in media for 24 h and then cultu~ with a secondary stimulus, 
as shown. Results represent four experiments and show thymidine incor- 
poration for the last 18 h of a 3-d secondary culture. I1.2 and I1,4 concen- 
trations were measured in supernatants at 24 h  of culture. 
6, top). In contrast, T  cells cultured with t-DR7 and IL-2 
were not tolerized and could proliferate on rechallenge with 
t-DR7/B7 or t-DR7/ICAM-1. These T cells also secreted 
IL-2 in response to t-DR7/B7  (Fig. 6, bottom). The maximal 
secondary proliferative response after primary culture with 
t-DR7 and IL-2 was ~50% of that observed when cells had 
been primarily stimulated with t-DR7/B7 aUo-APCs (Fig. 
4 b, top and Fig.  6, bottom). 
It has been observed previously that murine antigen-specific 
T cell clonal anergy can be reversed by prolonged culture of 
tolerized cells in the presence of exogenous IL-2 (45). In our 
model system, T cells tolerized to DR7 could briskly proliferate 
in the presence of IL-2 (Fig. 4 a, top and bottom). We there- 
fore sought to determine whether short culture with IL-2 
would reverse  DR7-spedfic tolerance. Viable alloreactive blasts 
isolated from primary cultures with t-DR7, t-DR7/B7,  or 
t-DR7/ICAM-1  allo-APCs, were cultured in the presence 
of 100 U/ml IL-2 for 3 d, extensively washed, and cultured 
in media for 3 d. Cells were subsequently restimulated for 
1-8  d  with  allo-APCs  t-DR7,  t-DR7/B7,  and  t-DR7/ 
ICAM-1. T cells primarily tolerized with t-DR7 or t-DR7/ 
ICAM-1 and cultured in IL-2 (Fig.  7, top and bottom), did 
not proliferate  in rechallenge with t-DR7,  t-DR7/B7,  or 
t-DR7/ICAM-1. In contrast, cells primarily sensitized with 
t-DR7/B7 and recuhured in IL-2 could respond in rechallenge 
with specific alloantigen and demonstrated maximal response 
at 3 d of culture (Fig.  7, middle). Rechallenge of all three 
populations with PMA and IM or third-party alloantigen 
resulted in significant  proliferative  response. 
Discussion 
Effective allogeneic transplantation in humans is limited 
by graft rejection and toxicity resulting from aggressive im- 
munosuppression. These life-threatening complications might 
be prevented or ameloriated by inducing aUoantigen-specific 
tolerance. One approach to achieve this objective is to iden- 
tify and block all relevant costimulatory signals involved in 
the generation of the T cell immune response to alloantigen. 
Considering the number of potentially relevant molecules ex- 
pressed  on APCs, we developed a culture system to deter- 
mine which of these molecules costimulate alloantigen-induced 
T cell proliferation and, more importantly, which can pre- 
vent the induction of human aUoantigen-specific  tolerance. 
To functionally isolate each of these costimulatory pathways, 
we prepared transfectants coexpressing HLA-DR and a can- 
didate costimulatory molecule. Here, we demonstrate that 
transfectants  coexpressing  HLA-DR7  and  either  B7  or 
ICAM-1 provided equivalent costimulation for alloreactive 
CD4 + T  cell  proliferation.  Although equivalent in  their 
ability to costimulate alloreactive T cell proliferation, costimu- 
lation provided by B7 and ICAM-1 differed in two respects. 
First,  B7 but not ICAM-1 induced significant  production 
of IL-2. Second, B7 but not ICAM-1 prevented the induc- 
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Figure  7.  I1.-2  cannot reverse the state of established toler- 
ance.  CD4 § T  cells were primarily stimulated with either 
t-DR7,  t-DR7/B7,  or t-DK7/ICAM-1 allo-APCs.  Viable 
blasts were cultured with I1,2 for 3 d, in media without II~2 
for 3  d,  and subsequently restimulated with a  secondary 
stimulus as indicated. Results represent five experiments and 
show thymidine incorporation for the last 18 h of a 3-d sec- 
ondary culture. 
1760  Prevention of Tolerance by B7 tion of alloantigen-specific tolerance. These results demon- 
strate that the delivery of a costimulatory signal that induces 
alloreactive T cells to proliferate is not sufficient to prevent 
the induction of tolerance. Moreover, these results demon- 
strate that this model system may permit us to determine 
which costimulatory molecules must be blocked in order to 
induce alloantigen-specific tolerance. 
Several lines of evidence support  the notion that B7- and 
ICAM-l-induced costimulation is not only due to improved 
adhesion between the APC and the T cell, but also to addi- 
tional,  distinct,  and independently mediated costimulatory 
signals. First,  presentation  of the HLA-DR7  and B7  or 
ICAM-1 molecules on separate transfectants  still results in 
costimulation, albeit in less proliferation  than when alloan- 
tigen and costimulatory molecules are expressed on the same 
cell. Second, although B7 and ICAM-1 deliver equivalent 
proliferative costimulatory signals, only B7 results in signifi- 
cant,  detectable IL-2 accumulation. Finally, only ICAM-1 
costimulation is CsA sensitive whereas B7, in agreement with 
previous observations (46, 47), is not. Taken  together, these 
data are consistent with the hypothesis that the proliferation 
induced by B7 and by ICAM-1 is the result of independently 
mediated costimulatory pathways. 
Herein, we have shown absence of proliferation and IL-2 
secretion in restimulation with the specific  aUoantigen, when 
alloreactive T cells were tolerized to DR7 after primary cul- 
ture with t-DR7 or t-DR7/ICAM-1 cells. Although toler- 
ized to specific  alloantigen, alloreactive T cells can proliferate 
with IL-2  and proliferate and secrete IL-2 in response to 
mitogens or third-party alloantigen. Challenge of these toler- 
ized cells with a HLA-DR7 homozygous lymphoblastoid line 
rather than with t-DR7/B7 transfectants resulted in modest 
proliferation.  This response might be due to stimulation by 
additional alloantigens expressed on the lymphoblastoid cells 
or  to  other  costimulatory molecules  that  can  overcome 
tolerance. 
Our results argue that inhibition of B7 costimulation will 
be essential but may not be sufficient to induce tolerance to 
alloantigen presented on donor grafts. These results are con- 
sistent with those reported by Tan et al. (48), who demon- 
strated that blockade of the B7:CD28/CTLA4 pathway with 
CTLA4-Ig resulted in hyporesponsiveness but not anergy of 
fully mismatched human PBMC. Although these investigators 
suggested that other costimulatory molecules  might be respon- 
sible for the failure of tolerance induction, the expression of 
all potential alloantigens and candidate costimulatory mole- 
cttles in both their primary and secondary  MLR did not permit 
them to determine which costimulatory pathways were crit- 
ical to the prevention of tolerance. Their results are less dra- 
matic than those reported by Lenschow et al. (31), who demon- 
strated in an in vivo murine model that inhibition of the 
B7:CD28/CTLA4 pathway with CTLA4-Ig resulted in long- 
lasting tolerance to xenogeneic human islet ceils. However, 
the inability  of other costimulatory signals to prevent the 
induction of tolerance in this xenogeneic model, might be 
due to the previous observations that the BT:CD28 pathway 
is conserved between humans and mice but that other essen- 
tial costimulatory molecules may not have this  degree of 
phylogenetic conservation (9, 12). Therefore, our model pro- 
vides an ideal system to functionally  dissect surface molecules 
that potentially prevent the induction or reverse the state of 
tolerance. Transfection of other alloantigens (e.g., HLA-DP, 
HLA-DQ, etc.) as well as other costimulatory molecules will 
be necessary to conclusively determine which costimulatory 
pathways must be blocked in order to induce tolerance to 
alloantigen. 
Since B7 costimulation upregulates IL-2 secretion, it was 
important to determine whether IL-2 alone could either pre- 
vent the induction or overcome the established state of toler- 
ance. Our results confirm and extend previous observations 
(45, 48) which show that the presence of IL-2 during induc- 
tion phase prevents the generation of antigen-specific toler- 
ance. Since transfectants isolate the relative contributions of 
alloantigen and specific costimulation for IL-2 secretion, we 
can more accurately evaluate the role of costimulatory signals 
and IL-2 in preventing the induction of tolerance. Here, we 
have  shown  that  alloantigen  accompanied  by  either  B7 
costimulation or exogenous IL-2 is sufficient to prevent the 
induction of tolerance. Since IL-2 is one of multiple cytokines 
that are regulated by B7 (42-44), our data suggest that IL-2 
is a critical consequence of B7 costimulation that prevents 
the induction of tolerance. This hypothesis is further sup- 
ported by the observation that ICAM-1 does not lead to de- 
tectable accumulation of IL-2 and does not prevent the in- 
duction of tolerance. However, neither we nor others have 
identified the molecular basis of how IL-2 prevents the in- 
duction of tolerance. 
Regardless of the mechanism, the ability of IL-2 to pre- 
vent the induction of tolerance has potential clinical implica- 
tions for allogeneic transplantation.  Our results suggest that 
the presence of any IL-2 in a microenvironment might permit 
the escape of alloreactive T cells from being rendered tolerant 
to a donor graft and thereby lead to only a partial  or tem- 
porary state of tolerance. The observation  that murine al- 
logeneic cardiac graft survival was only transiently prolonged 
by CTLA4-Ig blockade of the BT:CD28/CTLA4 pathway 
(32) is consistent with this hypothesis and suggests that ad- 
ditional costimulatory blockade or immunosuppression may 
be necessary to induce a state of long-term tolerance. The 
second clinically relevant issue is whether IL-2 in the microen- 
vironment can overcome the state of tolerance once it has 
been induced. This is obviously important to allogeneic trans- 
plantation,  as tolerance could be potentially broken during 
an active immune response. Since our experiments were not 
done in a T cell clonal system, we cannot definitively resolve 
this issue. Our data, however, do not support the conclusion 
that IL-2 alone can break alloantigen-specific tolerance. Bulk 
cultures  of alloreactive human CD4 §  T  calls tolerized  to 
DR7 readily proliferate in the presence of IL-2 alone. In this 
nondonal system, we do not know whether the proliferating 
T  cells are  alloantigen  specific or  alternatively  activated, 
nonspecific T  cell blasts. We have previously shown, how- 
ever, that anergized human tetanus toxoid-specific  T cell dories 
can proliferate to IL-2 alone (30). Moreover, our observation 
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when stimulated with third-party class II alloantigen, is con- 
sistent  with  the  assumption that  the bulk CD4 §  T  cell 
blasts were contaminated by activated T cells that were not 
specific for the tolerizing alloantigen. Taken together, these 
results suggest that tolerized T  cells can proliferate to IL-2 
and that the observed proliferation of DR7-tolerized CD4 + 
T cell blasts in bulk, nonclonal culture is likely due to prolifer- 
ation of both antigen-specific tolerized T cells and antigen- 
nonspecific activated T  cell blasts.  The capacity of tolerized 
T  cells to proliferate to IL-2 alone suggests that the IL-2 
receptor signal transduction pathway in tolerized T  cells is 
intact. 
In contrast to the reported results with mouse T cells (45), 
we have not been able to break tolerance with IL-2. After 
short-term culture with IL-2, rechallenge of DR7-tolerized 
cells with t-DR7/B7 does not result in proliferation. These 
results differ from those reported by Tan et  al.  (48)  who 
demonstrated in a nonclonal system that cells tolerized to 
alloantigen can proliferate in rechallenge with alloantigen and 
IL-2. Since those studies did not determine whether alloan- 
tigen-tolerized T  cells could proliferate to IL-2 alone,  they 
did not demonstrate that tolerance can be reversed. Moreover, 
they did not determine whether those IL-2/alloantigen stimu- 
lated cells could respond to rechallenge with alloantigen alone. 
Our results to date demonstrate that aUoantigen-specific toler- 
ance cannot be reversed by culture with IL-2 and are consis- 
tent with the hypothesis that IL-2 deprivation may induce 
apoptic cell death of previously tolerized T  cells. We favor 
this possibility since we have previously shown that toler- 
ized tetanus toxoid-specific T cell clones proliferate in response 
to IL-2 but undergo apoptosis when removed from the IL- 
2-rich environment (30).  The answer,  however,  awaits the 
examination of this question in an aUoantigen-specific T cell 
clonal system. If this result is confirmed, the concern that 
IL-2 may overcome tolerance will be a less serious clinical issue. 
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